RAP 0.00% 20.5¢ resapp health limited

Timely Information

  1. 59 Posts.
    lightbulb Created with Sketch. 15
    "ResMed profit jumps after rival’s own goal
    Share
    Sleep disorder and breathing devices company ResMed had a $US250 million ($350 million) windfall gain in 2022, thanks to an own goal by its rival Philips which was forced to recall some of its devices over a risky component in June last year.
    It helped propel ResMed to a 12 per cent increase in full-year revenue to $US3.6 billion, while net profit hit $US779.4 million, up 64 per cent."
    Full article https://www.copyright link/companie...-jumps-after-rival-s-own-goal-20220811-p5b96x
    Swift
 
watchlist Created with Sketch. Add RAP (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.